Stockscreener 앱 받기
27.94
4.45%
1.21
시간 외 거래:
27.50
-0.44
-1.57%
전일 마감가:
$26.73
열려 있는:
$27.06
하루 거래량:
552.24K
Relative Volume:
1.14
시가총액:
$1.30B
수익:
-
순이익/손실:
$-166.31M
주가수익비율:
-6.2643
EPS:
-4.4602
순현금흐름:
$-160.59M
1주 성능:
+6.77%
1개월 성능:
-8.22%
6개월 성능:
+21.13%
1년 성능:
+36.86%
1일 변동 폭
$26.95
$28.12
1주일 범위
$26.06
$28.01
52주 변동 폭
$16.10
$32.14
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
27.94 | 1.24B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2025-12-10 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-03-20 | 개시 | B. Riley Securities | Buy |
| 2025-03-10 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
모두보기
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
ArriVent BioPharma Shares Edge Lower Amid Sector CautionKAMA Signal - Newser
Cantor Fitzgerald reiterates Overweight rating on ArriVent stock By Investing.com - Investing.com Canada
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent delays Phase 3 trial to mid-2026 but extends cash runway to Q4 2027, reducing funding risk. - Pluang
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case - Seeking Alpha
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer - The Globe and Mail
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained - TipRanks
ArriVent BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering By Investing.com - Investing.com Australia
ArriVent BioPharma Updates At-The-Market Equity Offering Program - TipRanks
Arrivent Biopharma Enters Open Market Sale Agreement For Offer And Sell Common Stock Up To $250 MillionSEC Filing - TradingView
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering - Investing.com UK
ArriVent BioPharma (AVBP) files $250M ATM program with Jefferies - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility - Stock Titan
ArriVent BioPharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ArriVent BioPharma Reports First Quarter 2026 Financial Results - The Manila Times
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress - Stock Titan
ArriVent (Nasdaq: AVBP) Q1 2026 loss narrows while pivotal cancer trials progress - Stock Titan
ArriVent Phase 3 and Phase 1 cancer trials backed by $326M through 2027 - Stock Titan
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate - Yahoo Finance
ArriVent BioPharma Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance - BioWorld News
FDA clears new dual-target cancer drug for ovarian, endometrial trial - Stock Titan
Liquidity Mapping Around (AVBP) Price Events - Stock Traders Daily
FMR LLC (AVBP) discloses 3.02M shares, 6.8% stake in Arrivent Biopharma - Stock Titan
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital - MarketBeat
ArriVent BioPharma: A First Assessment (NASDAQ:AVBP) - Seeking Alpha
[ARS] ArriVent BioPharma, Inc. SEC Filing - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) details 2026 virtual meeting, board elections and CEO pay - Stock Titan
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained - TipRanks
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN
Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00 - MarketBeat
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cantor Fitzgerald initiates coverage of ArriVent BioPharma (AVBP) with overweight recommendation - MSN
Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month HighWhat's Next? - MarketBeat
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Stocks generating improved relative strength: ArriVent BioPharma - MSN
What macro factors move ArriVent (AVBP) stock most (Stalls) 2026-04-18Community Risk Signals - Xã Vĩnh Công
Arrivent Biopharma stock hits 52-week high at $29.56 By Investing.com - Investing.com Australia
Arrivent Biopharma Inc (AVBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arrivent Biopharma Inc 주식 (AVBP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Jul 11 '25 |
Option Exercise |
2.28 |
11,153 |
25,429 |
135,736 |
1.49%
0.12%
자본화:
|
볼륨(24시간):